The 85%+ hsCRP reduction is a strong biomarker signal for cardiovascular benefit, potentially positioning BGE-102 as a best-in-class NLRP3 inhibitor. With Phase 2 data expected by end-2026, traders should monitor trial initiation and enrollment trends as near-term catalysts. The lack of serious safety signals supports further development across multiple indications, increasing the asset's optionality.
BIOA drugs
BIOA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $19.61entry
- T+1 · 7mo ago −6.37%α −7.39% · $18.36
- T+5 · 7mo ago −11.07%α −12.15% · $17.44
- T+20 · 6mo ago −21.77%α −26.69% · $15.34
- T+60 · 4mo ago +13.00%α +6.10% · $22.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsCRP and other inflammatory biomarkers in obese participants with elevated inflammation. The company plans to initiate Phase 2 proof-of-concept trials in cardiovascular risk and diabetic macular edema by mid-2026, with data expected by end-2026 and mid-2027, respectively.
Key Facts
- BGE-102 achieved 85% median hsCRP reduction at 60 mg dose and 86% at 120 mg dose in participants with obesity and elevated inflammation
- 87% of participants on 60 mg dose achieved normalized hsCRP (<2 mg/L) by Day 21
- Drug was well tolerated with no serious adverse events or discontinuations
- Phase 2 cardiovascular risk trial planned for initiation in first half of 2026, with data by end of year
- Phase 1b/2a trial in diabetic macular edema to start mid-2026, data expected mid-2027
Financial Impact
Non-dilutive near-term catalyst with potential to revalue the stock based on upcoming clinical data readouts in 2026–2027
Risk Factors
- Phase 1 biomarker improvements may not translate into clinical outcomes in larger trials
- Competition from other NLRP3 inhibitors in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277765 |
Track record
11 reports on BIOA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.03% at T+5 after the May 8, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Viewing Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers